Sio Gene Therapies’ Exit From Oxford Biomedica Parkinson’s Collaboration Leaves Hole In Commercial Prospects
Firm Loses CEO
• By Ayisha Sharma
Generate a summary of this article
Listen to this article
Sio Gene Therapies is returning its rights for a Parkinson’s disease program to Oxford Biomedica, leaving observers regretting the loss of a big market opportunity, while the US firms seeks a new CEO.
Parkinson's Disease Represented The Biggest Market Opportunity For The Firm, One Expert Said. • Source: Alamy
Sio Gene Therapies, Inc. plans to call it quits on a Parkinson’s disease-focused licensing deal with Oxford BioMedica plc as it instead prioritizes its internal pipeline, prompting some analysts to lower their commercial projections for the firm.
Sio has also been hit by the departure of CEO Pavan Cheruvu to pursue new opportunities; he is being replaced...
Keep up with the top pharma business news of the week. On the go.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.